Lilly's targeted RET drug shrinks tumors in lung cancer trial

Eli Lilly and Co's LOXO-292, a experimental cancer drug the company acquired in January as part of its $8 billion takeover of Loxo Oncology, shrank tumors in nearly 70% of advanced lung cancer patients whose tumors carried specific abnormalities in the RET gene.

from Reuters: Health News https://ift.tt/2ZLrbpf
via IFTTT